Affymetrix Announces Winner of Anatrace Membrane Protein Award

Affymetrix, Inc. (Nasdaq: AFFX) today announced that Professor Tom Rapoport of Harvard Medical School and Howard Hughes Medical Institute is the winner of the 2010 Anatrace Membrane Protein Award. The award was presented at the Biophysical Society annual meeting in San Francisco and is sponsored by Anatrace, which is now part of Affymetrix.

The Anatrace Membrane Protein Award recognizes the scientist who has made the most outstanding contribution to understanding the structure or function of membrane proteins. Professor Rapoport’s work has clarified the mechanism by which proteins cross membranes and is the first to determine the structure of a protein-conducting channel.

The Rapoport group has also addressed how incorrectly folded proteins are transported through a membrane for cytosolic degradation, an important process in many diseases, and the mechanism by which the characteristic shape of an organelle is achieved. All of these projects concern fundamental aspects of membrane biology.

Tom Rapoport was elected to the National Academy of Sciences in 2005 and has spent much of his career studying protein translocation and other aspects of membrane biology. His laboratory has published many articles in leading journals, often using Anatrace products from Affymetrix.

“Professor Rapoport’s work clarifying the role of structure in protein function is an important finding as we seek to better understand the onset of disease,” said Kristin Yakimow, senior vice president and general manager of Affymetrix reagents. “Part of our mission is to deliver highly purified reagents to further scientific discovery. We are honored to be able to recognize Professor Rapoport’s work and to be a part of his research.”

About Anatrace products

Anatrace products from Affymetrix include unique, high-purity detergents and lipids designed to give researchers studying integral membrane proteins the confidence and peace of mind that come from accurate results. Products include lipid-like Fos-Choline® detergents, CYMAL® detergents, and PMAL™ polymeric solubilization aids.

About Affymetrix

Affymetrix technology is used by the world’s top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and not-for-profit research institutes. More than 1,800 systems have been shipped around the world and more than 20,000 peer-reviewed papers have been published using the technology.

Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company’s website at www.affymetrix.com.

Forward-Looking Statements

All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies,” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2008, and other SEC reports for subsequent quarterly periods.

NOTE: Affymetrix, the Affymetrix logo, and GeneChip® are registered trademarks of Affymetrix Inc. All other trademarks are property of their respective owners.

Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024